Patients with unexplained cytopenias often present a diagnostic dilemma with minimal morphologic or cytogenetic changes to identify the underlying disease process. We have used multidimensional flow cytometry in a study of patients with cytopenias and found that this technology established, changed, or refined the diagnosis in 17/121 patients. Using the flow cytometric technique of CD45 and right angle light scatter (SSC) gating with two additional markers in a three-color analysis, eight of 121 patients were found to have hairy cell leukemia (HCL), in the absence of definitive morphologic findings of HCL. Two additional patients were found to have non-Hodgkin's lymphoma (NHL). Myeloid abnormalities, myelodysplasia (MDS) or acute leukemia was detected in seven of 56 patients with unexplained pancytopenia. Six of 65 patients identified with cytopenias resulting from lymphoid neoplasms had been referred for bone marrow transplantation (BMT) with a presumptive diagnosis of MDS, with subsequent deferral of BMT upon correct diagnosis. The screening technique is incorporated into an extensive immunophenotyping scheme to identify hematopoietic abnormalities using multidimensional flow cytometry (MDF). HCL cells (detected as low as 1.3%) reside in the same position as normal monocytes in the CD45 and SSC plots but could be distinguished from monocytes based on the expression of HLA-DR without CD11b, and expression of CD19. Further phenotyping of the abnormal population confirmed immunoglobulin light chain restriction, CD11c, and CD25 expression. Non-Hodgkin's lymphoma was detected as aberrant mature lymphocytes expressing B lymphoid markers, CD5 and light chain restriction. Myeloid abnormalities were identified in the myeloblast or maturing myeloid cell fractions. The flow cytometric scheme described can be used in primary diagnosis. The technique is definitive, sensitive, and stresses the importance of distinguishing lymphoid from myeloid etiology of cytopenias.
Introduction
Single or multilineage cytopenias can be the result of inherited bone marrow failure syndromes, acquired disorders such as aplastic anemia, myelodysplasia (MDS), aleukemic leukemias, HCL, multiple myeloma, or may result from processes secondary to non-hematopoietic systemic diseases. 1 Often exhaustive work-ups fail to give a definitive diagnosis. Myelodysplasia may be a diagnosis of exclusion for patients in whom persistent transfusion-dependent cytopenias are present. Specifically, a diagnosis of refractory anemia as one presentation of MDS may be rendered in cases where morphologic dyspoietic features are generally minimal or equivocal, or only involving a single cell lineage. 2 These types of patients may be referred for BMT.
Patients with lymphoid neoplasms such as hairy cell leukemia (HCL) or non-Hodgkin's lymphoma (NHL) with low numbers of malignant can present with clinical and laboratory symptoms mimicking MDS, such as cytopenias and immune dysfunction. A significant proportion of HCL patients do not have splenomegaly, especially in early stages of the disease. 3 In particular, the diagnosis of HCL, while generally considered to have a very characteristic cytologic appearance with cytoplasmic projections and staining with tartrate-resistant acid phosphatase (TRAP), 4 may be difficult when these features are absent or when features are similar to other small lymphocyte proliferations. 5 If a specimen does not have a sufficient percentage of morphologically distinct hairy cells to suspect HCL or other lymphoid malignancies, a TRAP stain or additional workup is usually not performed and the diagnosis can be missed. In addition, the TRAP stain is somewhat difficult to perform correctly, is not a standard special stain, and is therefore not part of the usual workup for the morphologic assessment of pancytopenia. In many cases of overt HCL, marrows are fibrotic and inaspirable, or the TRAP stain may be equivocal. Moreover, bone marrow core biopsies in patients with HCL may morphologically appear to show aplastic anemia, even when carefully reviewed in retrospect. 6 Since complete clinical, immunologic, and molecular remissions are achievable in patients with HCL 7, 8 using specific therapy with 2-chlorodeoxyadenosine (2-CDA), a diagnosis of HCL must be established and should be seriously considered in all patients with unexplained cytopenias.
Multidimensional flow cytometry (MDF) is a technique that combines several quantitative cellular characteristics and uses them simultaneously to create a multidimensional space. 9 When applied to blood or bone marrow from hematologically normal individuals, cell populations are confined to highly reproducible positions dependent upon cellular lineage and maturation. 10 With careful selection of reagent combinations, phenotypically abnormal cell populations can be identified in a background of normal cells, since they occupy a space different from those of normally developing hematopoietic cells. 11 The aberrant cells can be detected at frequencies well below 1%. 12 The specific antigenic characteristics of the abnormal cells provide a means of classifying the cells based on their biology, ie specific gene expression.
During the initial referral workup at our institution, we unexpectedly discovered several patients who were referred for BMT with a diagnosis of myelodysplasia but actually had lymphoid malignancies when MDF was performed on bone marrow samples. The original presenting diagnostic cases had been previously carefully reviewed by morphology at both the referring institution and as consults by our pathologists. Specimens obtained at referral were also retrospectively reviewed by morphology. A diagnosis of lymphoid malignancy was not considered at presentation or review, and only the flow cytometry analysis was able to discern these neoplasms since the abnormal cells were at low percentages. TRAP stains or immunophenotyping at the referring institutions were not performed because a diagnosis of HCL or NHL was not considered in the differential diagnosis. We retrospectively extended the study to include non-BMT specimens referred to our flow cytometry laboratory with pancytopenia of unknown origin as the presenting diagnosis to review the occurrence of lymphoid malignancies in this setting. This study describes the use of a three-color flow cytometric screening panel for the distinction of B lymphoid from myeloid abnormalities in the context of cytopenias.
Materials and methods

Study population
Bone marrow aspirate and/or peripheral blood specimens from patients with a clinical history of pancytopenia of unknown etiology or a diagnosis under consideration of MDS due to cytopenias were referred for flow cytometric analysis. These patients came from two groups: 56 patients with specimens sent for flow cytometry with clinical findings of pancytopenia without an established diagnosis and 65 patients undergoing pre-allogeneic BMT work-ups with an incoming diagnosis of MDS. Six of the 65 patients in the pre-transplant group were found to have flow cytometric results disparate from those expected with MDS were included in this study. The remaining patients in the pre-transplant group with flow cytometric results or morphologic assessment confirming MDS were not analyzed further for purposes of this study.
Patients ranged in age from 21 to 89 years (median 51), 35 were female and 29 male. Informed consent for flow cytometric research studies was obtained using forms approved by the referring clinician or by the Institutional Review Board. Samples were routinely collected in heparin and analyzed within 24 h of collection.
Flow cytometric analysis
Monoclonal antibodies were obtained from the following sources:
Fluorescein isothiocyanate (FITC): CD2, CD5, CD8, CD20, CD25, CD71, HLA-DR, Anti-Kappa, Anti-Lambda (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA), CD30, CD33 (DAKO, Carpenteria, CA, USA). Phycoerythrin (PE): CD4, CD7, CD11b, CD11c, CD13, CD19, CD34, CD38, CD56 (Becton Dickinson), CD10 (DAKO), CD1a (Pharmingen, San Diego, CA, USA).
Peridinin-chlorophyll a (PerCP) CD45 (Becton Dickinson).
The procedure for labeling cells has been previously described. 10 In short, a working dilution of the titered monoclonal cocktails (Table 1) , CD45 peridinin-chlorophyll a (CD45 PerCP), and 0.1 ml well-mixed heparinized bone marrow or peripheral blood were incubated for 20 min at room temperature in the dark. The erythrocytes were lysed by adding 3 ml NH 4 Cl (0.83%, buffered with KHCO 3 pH 7.2) for 5 min at 37°C. The cells were then pelleted, washed once in phosphate-buffered saline (PBS)/2% fetal calf serum/0.1% sodium azide solution, then pelleted again and resuspended in PBS with 1% paraformaldehyde. Acquisition of data was performed on the CytoronAbsolute (Ortho Diagnostics, Raritan, NJ, USA) using ImmunoCount software (Ortho Diagnostics). Data analysis was performed on Winlist software (Verity House, Topsham, ME, USA). In a standard three-color immunofluorescence protocol, forward light scatter and SSC were collected along with three-color antibody combinations to generate five characteristics per cellular event. These five characteristics represent the coordinates for that event in a five-dimensional space, hence a multidimensional analysis. 9 Cellular debris and non-viable cells were first eliminated by electronic gating based on forward and SSC. 13, 14 Distinct lymphoid, monocytoid, myeloid, lymphoblast, and myeloblast populations present in the specimen were identified using CD45 and SSC (Figure 1a) , as previously described. 10, 11 A cellular differential of these five populations was provided by either directly gating on a discreet population identified by CD45 and side scatter, or by backgating using two-color antibody combinations to isolate cells of interest. 10, 11 Boolean gating logic schemes were used for gating so that the populations of interest were electronically separated for independent analysis and for distinguishing overlapping populations electronically. 9 It should be noted that the cellular proportions were expressed as per non-erythroid nucleated cell. 2 All specimens were processed with lysis of the erythroid cells using NH 4 Cl. In addition, the CD45-negative cells were excluded from the analysis thereby eliminating the residual nucleated erythroid cells, platelets and cell debris. 10 Samples were initially subjected to a screening panel (Table  1) as the first step in a two-tiered approach. If one or more of the abnormalities listed below were found on the screening panel results, specimens were then reflected to one or more of the secondary panels (myeloid, T or B lymphoid, hairy cell, or myeloma) listed in Table 1: HCL panel: CD19 expression on cells within the monocytoid region by CD45 and SSC. B lymphoid panel: increased mature B lymphoid cells within the lymphoid region by CD45 and SSC as identified by CD19 (greater than 15% of total non-erythroid or nucleated cells), or abnormal increased or decreased intensity of CD45 by mature B lymphoid cells or abnormal increased or decreased right angle light scatter patterns as compared to normal lymphocytes. 15 T lymphoid panel: increased mature T lymphoid cells within the lymphoid region by CD45 and SSC as identified by CD2 (greater than 15% of total non-erythroid or nucleated cells), 16 abnormal increased or decreased intensity of expression of CD2, 17 or increased NK cells as identified by CD11b (greater than 15% of total non-erythroid or nucleated cells). Increased peripheral blood contamination of bone marrow aspirate samples was assessed by the absence of phenotypically immature myeloid cells. Myeloid panel: increased proportion of myeloblasts (greater 10 Myeloma panel: increased plasma cells (greater than 2.0%) 16 as identified by bright expression of CD38. 19 When the screening panel did not detect any of the above abnormalities, the specimens were analyzed with the secondary myeloid panel to rule out abnormalities in the maturing myeloid populations as assessed by the additional myeloid and lymphoid antigens contained within that panel.
Morphology
Histopathologic examination of bone marrow aspirates and/or peripheral blood specimens was performed by staff at the referring institutions and consisted of standard WrightGiemsa-stained aspirates and peripheral smears, and H-and E-stained biopsies. The morphology was reviewed by pathologists at our tertiary center in cases where patients were referred for bone marrow transplant.
Results
Abnormalities among the B lymphoid cells were detected in 4/56 pancytopenic patients and 6/65 pre-BMT with an incoming diagnosis of MDS (Table 2 ). These abnormalities were initially detected based on an increase in B lymphoid cell proportion or when B lymphocytes appeared in regions where monocytes usually reside on CD45/SSC plots in the screening panel. Abnormal myeloid cells were detected in the myeloblast, monocyte or maturing myeloid regions in 7/56 pancytopenic patients.
No abnormal phenotypic populations were found in 45/56 of the pancytopenic patients ( Table 2 , non-neoplastic flow cytometric findings). Other, non-specific findings were based on the antigens expressed on each cell population. In 7/56 patients, reactive lymphocytes were identified based on an increase in lymphoid cells (greater than 15%) with HLA-DR and CD38 on T lymphoid cells. Decreased myelopoiesis was noted in 11/56 patients for whom the myeloid cell population was below 60% of total non-erythroid cells. 16 Normal phenotypes and proportions of cell populations were identified in the remaining 27 patients. The final diagnoses on patients without flow cytometric abnormalities were generally unavailable since our laboratory is a referral laboratory.
B lymphoid malignancies: hairy cell leukemia
Four of 56 patients in the unexplained pancytopenic group had immunophenotypic findings consistent with HCL. Additionally, 4/65 patients who were referrals for BMT with a presumptive diagnosis of refractory anemia, were found to have HCL. A unique phenotypic feature of this disease is that the abnormal hairy cells reside where normal monocytes are usually found when characterized by CD45 and SSC ( Figure  1b) . The three-color MDF screening panel detected these abnormal cells as HLA-DR and CD19 positive (Figure 1d , f) without expression of CD11b, whereas normal monocytes expressed HLA-DR, CD11b, and are negative for CD19 (Figure 1c, e) . Confirmation of the presence of hairy cells in these eight patients was then performed using the HCL panel ( Figure 2 ). The specific staining of the hairy cell population was performed by gating on the abnormal cell population identified by CD45/SSC (Figure 1b Abn-Mono). Hairy cell leukemia was confirmed by the expression of HLA-DR, CD19, CD11c, and light chain immunoglobulin restriction (three kappa positive and five lambda positive, Table 3 ). Two of the eight patients did not express CD20, while two patients did not express CD25. One patient expressed CD5 on the aberrant HCL population.
All patients with HCL were found to have concurrent populations of normal NK, T, and B lymphoid cells within the sample (Figure 1b , Lymph, and Figure 2b, d, f, h) . A relative lymphocytosis was observed in 7/8 patients with HCL identified, and the percentage of lymphocytes as assessed by the CD45 and SSC differential ranged from 18 to 78% of total cells. The majority of these lymphocytes consisted of normal T cells that ranged from 82 to 100% of the lymphoid compartment. Normal polyclonal B lymphoid cells ranged from 0.0 to 5.5% of total cells in these patients.
With use of the screening panel with CD45 and SSC gating in a three-color analysis, HCL cells were detected in specimens at low percentages, and were clearly delineated from the normal lymphocytes described above (Figure 2) . at 1.3% of total non-erythroid cells. The estimated lower limit of detection of these cells is 0.3% or less based on previous dilution experiments 12 and previous flow cytometric studies of known HCL. 20 Five of eight patients had significantly decreased numbers of normal monocytes in the bone marrow differential (normal mean = 2.8%; s.d. ± 1.2, limits 2.5-3.1 14 ), as previously described. 7, 21 In 2/8 patients, marrows were later re-submitted for MDF analysis post-treatment with 2-CDA to assess residual disease, and normal proportions of monocytes were observed as characterized by expression of HLA-DR, CD11b and CD14 (Figure 1 ). Hairy cell leukemic cells were below the flow cytometric level of detection.
By morphology, specimens in 6/8 HCL patients revealed non-specific changes. In two patients, histologic features suggested but were not definitive for a diagnosis of a lymphoid malignancy, Table 3 . Only two HCL patients presented with splenomegaly. Five of eight patients were treated with 2-CDA, 
B lymphoid malignancies: non-Hodgkin's lymphoma
Two of 65 additional patients referred for allogeneic BMT with a presumptive diagnosis of refractory anemia showed abnormal B lymphoid cells by the MDF screening panel. One patient presenting with pancytopenia, hemolytic anemia and mild lymphadenopathy was found to have B cell lymphoma in the bone marrow aspirate (20% of total non-erythroid cells). These small lymphocytes (abnormal cells were located in the Lymph region, Figure 1a ) exhibited expression of HLA-DR, CD19, CD20 with coexpression of CD5, FMC7, lacked CD23, and were restricted to lambda immunoglobulin light chain. These immunophenotypic findings were most consistent with a mantle cell lymphoma. 22 The second patient presented with pancytopenia and showed a monoclonal B lymphoid population (abnormal cells also located in the Lymph region, Figure  1a ) with expression of HLA-DR, CD19, co-expression of CD5 and CD20, CD23, and lack of FMC7 and restricted to kappa immunoglobulin light chain, an immunophenotype consistent with small lymphocytic lymphoma (18% of total nonerythroid bone marrow cells).
Myeloid malignancies: MDS/acute myeloid leukemia
In the unexplained pancytopenia group, in which the screening panel revealed abnormal myeloblasts in bone marrow aspirate samples, a full analysis of myeloid antigens was performed. Three of these patients had few or no circulating blasts in the peripheral blood. Multidimensional flow cytometric analysis of the bone marrow aspirates from these patients showed increased numbers of aberrant myeloblasts (32, 42 and 34%, respectively), and the diagnosis of aleukemic acute myeloid leukemia was made. Marrow specimens in an additional three non-BMT patients had less than 5% aberrant blasts by MDF, but abnormal patterns of expression of myeloid antigens on the maturing myeloid cells. 23, 24 As mentioned previously, pre-BMT patients with morphologic and/or cytogenetic evidence of MDS were not included in this study.
One patient presented with a history of neutropenia with no abnormal blasts in the marrow or peripheral blood. Peripheral blood cells were assessed for myeloid antigenic markers and revealed that 68% of the mature myeloid cells expressed CD16 dimly, while 51% of the mature monocytes did not express CD14. Further analysis revealed an absence of CD55 and the presence of CD59 on the maturing myeloid, monocytoid and erythroid cells. These findings suggested subpopulations of myelomonocytoid cells that lacked several phosphatidylinositol glycan anchored proteins including CD16, CD14 and CD55, consistent with paroxysmal nocturnal hemoglobinuria (PNH), 25 although CD59, which is often lacking in PNH clones, was expressed in this particular patient's abnormal myeloid and erythroid cells, as observed in PNH patients in other studies. 26, 27 A sucrose hemolysis test was positive.
Increased normal lymphoid cells
Seven patients were found to have reactive B and/or T lymphocytes and a relative lymphocytosis. Further immunophenotyping failed to show phenotypic abnormalities or monoclonality. Reactive T lymphoid cells expressed HLA-DR and CD38. These T lymphocytes were heterogeneous with both CD4-positive and CD8-positive subpopulations present. The intensities of CD2, CD5 and CD7 expression were normal. Within the B lymphoid lineage, the increased production of immature cells was established by the identification of an increased proportion of cells co-expressing CD5, CD10 and CD20. This phenotype was consistent with normal immature B lymphoid cells. 28 The B lymphoid cells were phenotypically polyclonal with respect to cell surface immunoglobulin light chain expression.
Increased normal plasma cells
Eight of 56 patients had greater than 2% plasma cells as determined by high expression of CD38. Six of these eight patients had decreased myelopoiesis with less than 60% myeloid cells present. Further analysis of the plasma cell population was performed using CD38 gating. 19 Plasma cells were polyclonal with equal expression of cytoplasmic kappa and lambda light chain immunoglobulin in all eight patients.
Normal myelopoiesis
Decreased myelopoiesis was identified in 11/56 patients with a markedly decreased myeloid to lymphoid ratio, with or without myeloid maturation, and no evidence of phenotypically abnormal myeloid or monoclonal lymphoid cells. Extensive analysis of myeloid antigens showed the myeloblast and maturing myeloid cells to have typical heterogeneous populations as observed in normal hematopoiesis, 29 however, their numbers were disproportionately low. The absence of abnormalities in the myeloid lineage with a decrease in myelopoiesis was more consistent with an aplastic rather than myelodysplastic or leukemic process.
A single patient had an inadequate marrow sample, but phenotypically normal myeloblasts were detected by flow cytometry in the peripheral blood. Prominent marrow fibrosis was evident on a reticulin stain of the core biopsy. These results taken together provided a final diagnosis of primary myelofibrosis.
Twenty-seven of 56 patients had no abnormalities on the screening panel. Upon further immunophenotypic analysis, these patients were found to have either normal myelopoiesis with normal proportions of lymphocytes, maturing myeloid cells, monocytes, lymphoblasts, and myeloblasts, 16 or increased immature myeloid forms (shift to the left). Increased proportions of immature myeloid cells were detected by assessment of myeloid maturational stages as compared to bone marrows obtained from hematologically normal individuals. 10, 29 A definitive cause for the pancytopenia observed in these patients remained unclear, but may have been due to drug reactions, infections, or other non-neoplastic causes.
Discussion
A common and difficult problem in pancytopenic patients referred to a tertiary center is the distinction between hypoplastic MDS, severe aplastic anemia, PNH or HCL, particularly when no cytogenetic abnormalities are present. 30 A 2021 lymphoid malignancy was not in the differential diagnosis at presentation at the referring institution or when referred for bone marrow transplant in the patients described. The differential diagnosis is often clouded by the marrow being inaspirable and compounded by the fragile nature of the scanty numbers of cells on aspirate smears. Often samples are small, and there are limitations to cytologic distinctions based only on sections from biopsies or particle preparations. The diagnostic distinctions of such hypoplastic specimens may rely on subtle and minimal changes involving less than 10% of a lineage with minor megaloblastic vs regenerative changes, eg small megakaryocytes, late megaloblastic erythroid cells, or left shifted myelopoiesis. In such cases, MDF performed on an aspirate or from cells disaggregated from a marrow biopsy is far more sensitive, specific and reproducible. For example, the cases of HCL in the current series were atypical in that splenomegaly and circulating hairy cells were, for the most part, absent. Moreover, HCL variants may be missed by morphology if the usual classic patterns are not present and a TRAP stain may not be performed. Cases 1 and 7 were classified as HCL variants, and both patients had been referred for transplant with a diagnosis of MDS. In our bone marrow transplant center, definitive identification by MDF using a panel of antibodies specific for HCL has therefore replaced the traditional TRAP cytochemical stain. In the past, flow cytometry has not played a major role in the differential diagnosis of unexplained pancytopenia, single lineage cytopenias, or suspicion of MDS. However, recent studies have shown that MDF can detect small populations of abnormal cells in morphologically normal bone marrow. 31 The results described in this paper indicate that flow cytometry can provide more than simple validation of a morphologic diagnosis and greatly extend the utility of MDF.
The first group of 56 patients who were studied presented with a primary clinical finding of pancytopenia of unknown etiology. In four of these patients, HCL was diagnosed because of MDF, and seven exhibited definitive myeloid abnormalities. The frequency with which MDF detected lymphoid abnormalities in pancytopenic patients is most remarkable when it is considered that the second group of patients were pre-BMT. These 65 patients with an assigned diagnosis of MDS were being evaluated for an allogeneic bone marrow transplant. Flow cytometric analysis revealed six patients to have lymphoid rather than myeloid abnormalities, four with HCL and two with NHL.
In a previous study of patients with unexplained leukopenia discovered on routine physical exams that included bone marrow and peripheral blood smear evaluations, cytogenetics and stem cell cultures, 2/86 patients were found to have HCL. 32 Morphology was used in the study for identification of HCL, and it is conceivable that the number of patients with lymphoid malignancies may have been higher if a flow cytometric analysis had been used. This study and the current study suggest an increased role for flow cytometry in the routine workup of pancytopenia and MDS. This applies in particular when the morphology is suboptimal, or the dyspoietic changes are mild.
Furthermore, if HCL were a diagnosis of suspicion in pre-BMT patients with presumed MDS, a single or two-color analysis could not adequately distinguish HCL from these normal components when the neoplastic cells were present at low percentages. Previous studies with cases of known HCL found a two-color analysis incapable of identifying HCL cells at levels less than 2%, and light chain restriction could not be shown on conventional forward vs SSC gating due to dilution by normal polyclonal B lymphocytes. 20 The results from the current study also found a two-color analysis to be inadequate when HCL was present at low percentages. The method of a three-color analysis using CD45 and SSC gating, however, detected HCL in this study at a level of 1.3%, and potentially can detect abnormal lymphoid cells at levels below 0.3%, 12 due to electronic isolation of the population of interest. Moreover, a definitive diagnosis of HCL may be difficult when normal polyclonal B lymphoid cells are also present, as observed in several of the study patients with HCL. Unless HCL cells are isolated electronically from normal B lymphoid cells, they could potentially obscure the monoclonal nature of the HCL cells. A two-color analysis may detect populations of CD19/CD25-positive and CD19/CD11c-positive cells, however, without confirmation of monoclonality, these cells may be overlooked or classified as activated mature memory B cells in patients in whom the diagnosis of HCL is not being considered. Therefore, a multi-color complex analysis is requisite for flow cytometric screening of patient's with suspected HCL.
The screening panel described above may also detect other B lymphoid malignancies such as plasma cell myeloma and non-Hodgkin's lymphomas. 12, 33 The use of the CD38/CD71 combination can detect increased proportions of plasma cells in a bone marrow aspirate. 19 Although none of the pancytopenic study patients were found to have monoclonal plasma cell populations as determined by increased expression of CD38 and intracytoplasmic immunoglobulin restriction, 33 the potential exists for distinguishing myeloma from other B lymphoid malignancies including HCL and HCL variants. 34 Previously undetected monoclonal B cell malignancies were discovered in two of the pancytopenic patients studied by use of the MDF screening with subsequent appropriate immunophenotypic panels that delineate and classify non-Hodgkin's lymphomas. 22, [35] [36] [37] [38] It should be emphasized that small clonal B cell populations incidentally detected by flow cytometry at low percentages may not have clinical significance, but patients should be followed over time to rule out frank nonHodgkin's lymphomas.
Complex flow cytometric analyses of patients with unexplained cytopenias can potentially corroborate morphology in cases where a myeloid neoplasm is truly present. In acute myeloid leukemia, myeloblasts from MDS patients demonstrated aberrant myeloid or monocytoid antigen expression (or both), however, the abnormalities were observed on more mature cells as well. 23, 24 There was a high correlation between morphology and MDF analysis for blast cell counts as previously described. 39 In cases of refractory anemia without excess blasts, the abnormalities were confined to the mature populations. Further studies are needed to define the role of flow cytometry in myeloid diseases such as MDS.
Significant differences in cellular composition and antigen expression were found in the bone marrows of patients who did not reveal antigenic atypia. The clinical and diagnostic relevance of these differences can only be determined by long-term follow-up of patients comparing clinical and laboratory findings. 32 The importance of recognizing HCL, even in low percentages of bone marrow cells and peripheral blood is highlighted by this study. Given the excellent response of HCL to chemotherapy, consideration of BMT can be deferred when HCL is discovered. An early diagnosis of this disease may also prevent the complications associated with HCL such as serious infections and splenomegaly. Multidimensional flow cytometric analysis is simple, cost effective, and in the present series identified six patients in whom BMT was not indicated.
